244 related articles for article (PubMed ID: 28548198)
1. [Diabetic ketoacidosis with mild hyperglycemia associated with the use of canagliflozin. Report of one case with type 1 diabetes].
Novik A V; García B C; Oliva I D
Rev Med Chil; 2017 Mar; 145(3):393-396. PubMed ID: 28548198
[TBL] [Abstract][Full Text] [Related]
2. Sodium-glucose cotransporter 2 inhibitors and diabetic ketoacidosis.
Bloomgarden ZT
J Diabetes; 2016 Mar; 8(2):175-6. PubMed ID: 26611882
[No Abstract] [Full Text] [Related]
3. Euglycemic Diabetic Ketoacidosis with Persistent Diuresis Treated with Canagliflozin.
Adachi J; Inaba Y; Maki C
Intern Med; 2017; 56(2):187-190. PubMed ID: 28090050
[TBL] [Abstract][Full Text] [Related]
4. Sodium-glucose cotransporter 2 inhibitor-associated diabetic ketoacidosis: Report of two cases with hyperglycemic ketoacidosis in type 1 diabetes.
Harati H; Sharma V; Motazedi A
J Diabetes; 2016 Jan; 8(1):165. PubMed ID: 26211700
[No Abstract] [Full Text] [Related]
5. Euglycemic diabetic ketoacidosis with canagliflozin: Not-so-sweet but avoidable complication of sodium-glucose cotransporter-2 inhibitor use.
Clement M; Senior P
Can Fam Physician; 2016 Sep; 62(9):725-8. PubMed ID: 27629668
[No Abstract] [Full Text] [Related]
6. EUGLYCEMIC DIABETIC KETOACIDOSIS AND SEVERE ACUTE KIDNEY INJURY SECONDARY TO OFF LABEL USE OF SODIUM GLUCOSE COTRANSPORTER-2 INHIBITOR IN A TYPE-1 DIABETIC PATIENT.
Tahir H; Wani A; Daruwalla V; Daboul N; Sagi J
J Ayub Med Coll Abbottabad; 2015; 27(4):923-4. PubMed ID: 27004352
[TBL] [Abstract][Full Text] [Related]
7. Sodium-glucose Cotransporter 2 Inhibitor-induced Diabetic Ketoacidosis in a Type 2 Diabetic Patient.
Ramirez Tello EM; Orellana-Barrios MA; Nugent K
Am J Med Sci; 2016 Jun; 351(6):634-5. PubMed ID: 27238930
[No Abstract] [Full Text] [Related]
8. Diabetic ketoacidosis associated to canagliflozin in type 2 diabetes.
González Sanchidrián S; Gómez-Martino Arroyo JR; Labrador Gómez PJ
Med Clin (Barc); 2017 Feb; 148(4):e19-e20. PubMed ID: 28041622
[No Abstract] [Full Text] [Related]
9. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.
Burke KR; Schumacher CA; Harpe SE
Pharmacotherapy; 2017 Feb; 37(2):187-194. PubMed ID: 27931088
[TBL] [Abstract][Full Text] [Related]
10. Non-occlusive Mesenteric Ischemia with Diabetic Ketoacidosis and Lactic Acidosis Following the Administration of a Sodium Glucose Co-transporter 2 Inhibitor.
Gocho N; Aoki E; Okada C; Omura K; Hirashima T; Suzuki N; Tanaka H; Omori Y
Intern Med; 2016; 55(13):1755-60. PubMed ID: 27374678
[TBL] [Abstract][Full Text] [Related]
11. Diabetic Ketoacidosis With Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes.
Peters AL; Henry RR; Thakkar P; Tong C; Alba M
Diabetes Care; 2016 Apr; 39(4):532-8. PubMed ID: 26989182
[TBL] [Abstract][Full Text] [Related]
12. Euglycemic Diabetic Ketoacidosis with Elevated Acetone in a Patient Taking a Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor.
Andrews TJ; Cox RD; Parker C; Kolb J
J Emerg Med; 2017 Feb; 52(2):223-226. PubMed ID: 27717592
[TBL] [Abstract][Full Text] [Related]
13. Euglycemic Ketoacidosis Caused by Sodium-Glucose Cotransporter 2 Inhibitors: A Case Report.
Bobart SA; Gleason B; Martinez N; Norris K; Williams SF
Ann Intern Med; 2016 Oct; 165(7):530-532. PubMed ID: 27699391
[No Abstract] [Full Text] [Related]
14. ‘Euglycemic’ Ketoacidosis in a Patient With Type 2 Diabetes Being Treated With Canagliflozin.
Danford C; Chan P; Magill SB
WMJ; 2016 Aug; 115(4):206-9. PubMed ID: 29099159
[TBL] [Abstract][Full Text] [Related]
15. Euglycemic diabetic ketoacidosis in type 2 diabetes treated with a sodium-glucose cotransporter-2 inhibitor.
Jazi M; Porfiris G
Can Fam Physician; 2016 Sep; 62(9):722-4. PubMed ID: 27629667
[No Abstract] [Full Text] [Related]
16. Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literature.
Bonora BM; Avogaro A; Fadini GP
Diabetes Obes Metab; 2018 Jan; 20(1):25-33. PubMed ID: 28517913
[TBL] [Abstract][Full Text] [Related]
17. Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Sodium-Glucose Cotransporter-2 Inhibitors - A Case Series.
Sharma PV; Jobanputra YB; Lewin K; Bagatell S; Lichtstein DM
Rev Recent Clin Trials; 2018; 13(2):156-160. PubMed ID: 29542418
[TBL] [Abstract][Full Text] [Related]
18. [Severe diabetic ketoacidosis, acute kidney injury and dehydration due to canagliflozin in type 2 diabetes mellitus patient: Atypical clinical presentation].
Moreno Obregón F; Espino Montoro A; Marín Martín J; León Jiménez D
Aten Primaria; 2019 Dec; 51(10):664-666. PubMed ID: 31326123
[No Abstract] [Full Text] [Related]
19. An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes.
Messana JA; Schwartz SS; Townsend RR
Vasc Health Risk Manag; 2017; 13():43-54. PubMed ID: 28255241
[TBL] [Abstract][Full Text] [Related]
20. Possible association between diabetic ketoacidosis and use of sodium-glucose co-transporter 2 inhibitor in a 17-year-old youth with type 2 diabetes.
Shamchuk A; Doulla M; Jetha M
CMAJ; 2021 Sep; 193(35):E1385-E1388. PubMed ID: 34493565
[No Abstract] [Full Text] [Related]
[Next] [New Search]
